Published on: July 23, 2015
by Sarah C. P. Williams for Science Now:
It’s been a controversial strategy for more than a decade – giving estrogen hormone replacement therapy (HRT) to women to treat hot flashes, depression, and menopause-induced dementia. Although the therapy often works, it can also cause cancer, heart disease, and stroke. Now, scientists have found a way to boost estrogen only in the brain, a success in rats that may translate to safer treatments for people.
“This could be very applicable for women suffering from hot flashes or depression for whom estrogen therapy is really counter-indicated,” says neuropharmacologist Roberta Brinton of the University of Southern California in Los Angeles, who was not involved in the new work.
When a woman naturally reaches menopause—most often in her 50s—or does so prematurely, for reasons such as a hysterectomy or cancer treatment, levels of estrogen in her body begin to plummet. The hormonal changes can cause hot flashes, depression, and, over time, contribute to women’s risk of developing dementia and osteoporosis. Throughout the latter half of the 20th century, physicians commonly prescribed estrogen HRT to women going through menopause to help ease this transition as well as prevent the long-term effects of estrogen deprivation. Around the turn of the century, though, researchers noticed that women on HRT had an increased risk of heart disease, uterine and breast cancers, and strokes, and doctors generally stopped prescribing the drugs. Even pills that combined estrogen with other hormones meant to alleviate those problems didn’t fare any better when it came to dangerous side effects.
Researchers led by biochemist Laszlo Prokai of the University of North Texas Health Science Center in Fort Worth were studying the production of estrogen in the body when they realized that one estrogen-generating pathway was only active in the brain. A compound called 10β,17β-dihydroxyestra 1,4 dien-3-one (DHED), they found, relies on an enzyme in the brain to be converted from its “prodrug” form into the active form of estrogen; other organs in the body use different starting blocks to generate the hormone. That means that, theoretically, treating animals with DHED would only result in an estrogen increase in the brain, not in the heart, uterus, or breast tissue, where it can cause unwanted side effects.
And indeed, when the researchers gave rats doses of DHED, estrogen levels in their brains increased, whereas levels elsewhere in the body remained stable. What’s more, in female rats lacking ovaries—prone to hot flashes, depression, memory problems, and stroke—DHED reversed theses nervous system-linked menopause symptoms without any detectable impacts on the rest of the body, the scientists report online today in Science Translational Medicine.
“Because this prodrug remains completely inactive everywhere else in the body, you can remedy the neurological and psychiatric symptoms associated with estrogen deficiency while avoiding side effects in the rest of the body,” Prokai says. DHED could be particularly useful in treating women who prematurely enter menopause after surgery, because they have the most drastic changes in hormone levels and often deal with symptoms for the longest, he points out. Prokai’s group has already launched nonhuman primate studies of the therapy.
But although the drug holds promise for helping some women, such as those who have specific risk factors for cancer, Brinton says, it may not be an ideal first-line treatment for estrogen-deficiency in many others. “Specifically targeting the brain might have some potential advantages but you aren’t protecting against osteoporosis and other conditions associated with the loss of hormones,” Brinton says. “There are certainly organ systems other than the brain which benefit from estrogen.” Prodrugs specific to those other organs—such as bones—would have to be developed to boost estrogen elsewhere in the body, she says.
Older people who report greater levels of social engagement have more robust gray matter in regions of the brain relevant in dementia, according to new research led by scientists at the University of Pittsburgh Graduate School of...
In a new study, University of Nebraska–Lincoln sociologist Marc A. Garcia explored how educational attainment can benefit cognitive health in later life, and whether there are differences in its benefits among minorities. Garcia and his co-authors...
A genetic variation in some people may be associated with cognitive decline that can’t be explained by deposits of two key proteins associated with Alzheimer’s disease, amyloid β and tau, according to a study...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.